Johnson & Johnson’s Janssen Biotech submitted an application to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA) for its single-dose COVID-19 vaccine. The EUA submission is based on topline data from the Phase III ENSEMBLE trial. If the FDA grants authorization, J&J indicates it has the vaccine ready to ship immediately.
J&J Sends One-Shot Vaccine to FDA, Emergency Use Authorization Expected End of February
COVID-19
New content will be added as they become available. Check back often, or Subscribe to Updates to receive emails as new information becomes available. Have an article to share? Submit an Article to be added to Education Support Hub.
Explore Programs
After School Programs | Community Programs | Summer Programs | View All
